Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€217.60

€217.60

0.280%
0.6
0.280%
€215.00
 
22:26 / Tradegate WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for ResMed

sharewise wants to provide you with the best news and tools for ResMed, so we directly link to the best financial data sources.

News

Why ResMed Stock Tumbled by 5% Today: https://g.foolcdn.com/editorial/images/791199/medical-professional-with-hand-on-head.jpg
Why ResMed Stock Tumbled by 5% Today

Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new

How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?: https://g.foolcdn.com/editorial/images/782157/mfm_24.jpg
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?

ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other

Why ResMed Stock Is Soaring Today: https://g.foolcdn.com/editorial/images/774544/cpap-mask-person.jpg
Why ResMed Stock Is Soaring Today

Shares of ResMed (NYSE: RMD) had soared 16.2% higher as of 11:50 a.m. ET on Friday. The big jump came after the healthcare technology company reported results on Thursday evening for its fiscal 2024

Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank: https://g.foolcdn.com/editorial/images/773323/person-in-a-lab-looking-through-a-microscope.jpg
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank

For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side).

Some good news from a clinical trial conducted by Eli Lilly

Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market: https://www.marketbeat.com/logos/articles/med_20240630174256_charty-lly.jpg
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is